IL10 and Alzheimer disease: Though our data suggests that inhibition of intracerebral Il4 or Il10 signaling via decoy receptors could represent a novel approach to AD immune therapy, the differences in the brain expression of these cytokines between mice and humans, may present a translational dilemma.